Cure8 trial brief
A new Phase 2 trial is testing MK-8690 as a potential subcutaneous treatment for moderate–severe ulcerative colitis, with clinical remission at 12 weeks as the primary goal. Positive results could point to an additional therapy option for people who failed or are intolerant to current treatments.
Adults with moderately to severely active ulcerative colitis, clinicians who treat UC, and researchers following experimental IBD therapies or drug development.
This ClinicalTrials.gov record describes a recruiting Phase 2 trial (planned n≈100) comparing MK-8690 versus placebo given by subcutaneous injection for 12 weeks. Nonresponders may receive open-label MK-8690 in a subsequent period, and responders can continue on treatment for an extension of about 42 weeks.
Eligibility and outcomes: Adults 18–75 with moderately to severely active UC who meet protocol stability and prior-treatment criteria are eligible. The primary outcome is the percentage achieving clinical remission per the Modified Mayo Score at Week 12; endoscopy (endoscopic subscore) is part of that definition.
Practical note: This is a trial record, not a result. If you are considering participation, discuss eligibility, potential risks, and alternatives with the study team and your treating clinician.
This ClinicalTrials.gov entry is a trial protocol (Phase 2, recruiting); it does not report efficacy or safety results. The primary endpoint includes an endoscopic component (Modified Mayo Score), so trial participation involves endoscopy assessments. Contact the listed study sites or your clinician for up-to-date status and eligibility details.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Patients and families with pediatric UC may be interested because the study tests FMT plus partial enteral nutrition as a potential new treatment approach for children who haven’t responded to standard therapy and as a...
The trial is testing risankizumab alone and in combination with investigational ABBV antibodies for moderate-to-severe Crohn’s disease and ulcerative colitis — findings could inform future treatment choices and...
This reports Phase 2b trial results for duvakitug showing improved remission and endoscopic response versus placebo in UC and CD—early evidence that could lead to a new treatment option if later trials confirm benefit...
